Also BTX's subsidiary has spine regen and cancer vaccine products about to start trials.........both BILLION $ PRODUCTS.
WHO else has such an extensive pipeline?!!! It's all just starting here so get in while you can.
Again Dr. West is a genius, have other people test your product and pay for clinical studies.
Expect great things from AST & BTX. Hoping to add more shares here before spine trials actually start and we make the headlines. The Mothership is at 3.11 a share and cancer diagnostic products to be introduced in the EU by years end. Win-Win.
All animal and preclinical studies passed with flying colors. stem cell R&D products, LifeMap app, cancer diagnostics, cosmetic surgery, dendritic cancer vaccines, cartilage, tendon & bone regen, spine regen, heart and blood regen, AMD program.....even if two of these programs were to fail BTX still is probable of making BILLIONS within a few short years.
BUY & HOLD & GET RICH.
Dr. West genius coming to fruition....Hystem R&D outside of company paying off.
Belgium University hystem clinical trials to be used for vocal scarring.....Clinical trials FULLY paid for, hats off to Michael West.
BTX revs up 93%, every quarter BTX will grow exponentially thanks to LifeMaps.
“Watching the plummeting costs of sequencing the genome, and the rapid rise of other digitized medical data, we recognized that we had a good foundation [at BioTime] to build a leading service and product to manage all that data,” adds West. “Not just for researchers, but for the public in general.”
Low Profile Company, High Profile Partnership
For many observers, however, the real buzz around the soft launch of LifeMap Solutions will be its close partnership with the Icahn Institute. This is the home of Dr. Eric Schadt, who has attracted a reputation for shaking up fundamental ideas about biology and disease.
BTX is at a 5 yr low and by the end of this year will start to have products come to market. Cosmetic surgery device in the EU as well as next-gen cancer diagnostic products. Over next 3-6 months you want to be in BTX.
Should be flying high in Autumn when lung, breast and bladder cancer diagnostics near completion. Weill Cornell, Wistar, UCLA and Mt Sinai partnerships are just the start!
BTX the only stem company with FDA cleared hydrogel device!
BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA’s Center for Devices and Radiologic Health that Premvia™ has been cleared for marketing as a Class II medical device.
Our subsidiaries expanding, good thing we got 24 MIL in grants over the last few months.
Sentiment: Strong Buy
Good news for BTX & UCLA partnership.....New peer-review paper out in UK proving that stem cells are highly beneficial to stroke victims.
Another disruptive/HUGE money maker for BTX to go into clinical trials soon:
BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has entered into an exclusive license agreement with the University of California, Los Angeles (UCLA) for novel technology related to the treatment of stroke. The licensed technology, developed in the laboratories of Tom Carmichael, MD, PhD of UCLA’s Department of Neurology, at the David Geffen School of Medicine, uses one of BioTime’s HyStem® hydrogels to deliver locally released growth factors to improve recovery from stroke. Pre-clinical studies have demonstrated that the localized delivery of growth factors such as brain-derived neurotrophic factor (BDNF) results in a statistically significant improvement in post-stroke motor function in a murine model of ischemic stroke.
Concurrent with the execution of this exclusive license agreement, BioTime has entered into a Sponsored Research Agreement with UCLA to support on-going pre-clinical work in Dr. Carmichael’s laboratory to advance the understanding of this technology and develop data in support for the potential filing of an Investigational New Drug Application (IND) for human clinical trails.
Baltbear and jet pro DONT want to hear the words slow and steady, they(he) has been buying in and out of BTX for years.
A) BTX releases PanC-DX (bladder, lung & breast cancer diagnostic products)
B) BTX moves into $12-20 range
Genetic diagnostic app for patients can be a game changer especially if it becomes the platform of choice. Mt Sinai is a school for medicine teaching next gen medical student the latest, could be a key spring board.
Sentiment: Strong Buy
Biotimes adipose/ECM IP is a clear winner IMO.